Ads
related to: parp inhibitors ovarian cancer review- About PARP Inhibitors
Learn About How Treatment Works.
Learn About Maintenance Therapy.
- Safety And Side Effects
Read Important Safety Information.
Learn More About A Treatment.
- Treatment Effectiveness
Read About How Treatment Works And
Its Benefits And Risks In Patients.
- Tablet Dosing Info
Learn About Tablet Dosing For
An Ovarian Cancer Treatment.
- First-Line Maintenance
Learn About First-Line Treatment.
Download Helpful Resources & Info.
- Talk To Your Doctor
Get Resources To Help Stay Informed
To Make Your Conversation Easier.
- About PARP Inhibitors
Search results
Results From The WOW.Com Content Network
Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II:
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. [3] [4] [5] It is taken by mouth. [3] [4] It is a PARP inhibitor.
Thus, PARP inhibitors of various types (e.g. olaparib) for BRCA mutant breast and ovarian cancers can extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. There are several additional classes of novel PARP inhibitors that are in various stages of clinical development. [21]
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [2] [5] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. [5] [6]
Ads
related to: parp inhibitors ovarian cancer reviewgotoper.com has been visited by 10K+ users in the past month